Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

$24.99

Common-Size Income Statement

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Gilead Sciences Inc., common-size consolidated income statement

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Product sales
Cost of goods sold
Gross profit on product sales
Royalty, contract and other revenues
Research and development expenses
Acquired in-process research and development expenses
In-process research and development impairment
Selling, general and administrative expenses
Operating income
Interest expense
Other income (expense), net
Income before income taxes
Income tax (expense) benefit
Net income
Net loss attributable to noncontrolling interest
Net income attributable to Gilead

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Income statement item Description The company
Operating income The net result for the period of deducting operating expenses from operating revenues. Gilead Sciences Inc. operating income as a percentage of product sales decreased from 2021 to 2022 but then slightly increased from 2022 to 2023.
Income before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Gilead Sciences Inc. income before income taxes as a percentage of product sales decreased from 2021 to 2022 but then slightly increased from 2022 to 2023.
Net income attributable to Gilead The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Gilead Sciences Inc. net income attributable to Gilead as a percentage of product sales decreased from 2021 to 2022 but then increased from 2022 to 2023 not reaching 2021 level.